Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

ALEXION PHARMACEUTICALS

(ALXN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Alexion Pharmaceuticals : Raises Outlook After Strong First Quarter

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2019 | 07:13am EDT

By Bowdeya Tweh

Alexion Pharmaceuticals Inc. (ALXN) raised its profit and sales outlook this year after posting stronger-than-expected first-quarter results, bolstered by growth in Soliris and newer treatments like Ultomiris.

Profit in the latest period more than doubled to $587.9 million, or $2.61 a share.

Excluding one-time items, Alexion earned $2.39 a share. Analysts polled by FactSet expected $2.21 a share.

Revenue rose 23%, to $1.14 billion, as analysts expected $1.13 billion.

For the full year Alexion expects per-share earnings of $6.76 to $7.96, or $9.25 to $9.45 as adjusted, on revenue of $4.68 billion to $4.75 billion. The company had expected per-share earnings of $6.14 to $7.26, or $9.10 to $9.30 as adjusted, on $4.63 billion to $4.7 billion in revenue.

Write to Bowdeya Tweh at bowdeya.tweh@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALEXION PHARMACEUTICALS
06/21ALEXION PHARMACEUTICALS : U.S. FDA Accepts Supplemental Biologics License Applic..
AQ
06/20ALEXION PHARMACEUTICALS : Gets FDA Priority Review of Ultomiris in Kidney Disord..
DJ
06/20ALEXION PHARMACEUTICALS : U.S. FDA Accepts Supplemental Biologics License Applic..
BU
06/19ALEXION PHARMACEUTICALS : ULTOMIRIS Receives Marketing Authorization from Japan'..
AQ
06/18ALEXION PHARMACEUTICALS : ULTOMIRIS® (ravulizumab) Receives Marketing Authorizat..
BU
06/14ALEXION PHARMACEUTICALS : Positive Phase 3 Extension Data for ULTOMIRIS® (ravuli..
BU
05/17ALEXION PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Hold..
AQ
05/13ALEXION PHARMACEUTICALS : to Present at the UBS Global Healthcare Conference
BU
05/13ALEXION PHARMACEUTICALS : to Present at the RBC Capital Markets Annual Healthcar..
BU
05/06ALEXION PHARMACEUTICALS : New England Journal of Medicine Publishes Positive Pha..
AQ
More news
Financials ($)
Sales 2019 4 767 M
EBIT 2019 2 625 M
Net income 2019 1 760 M
Finance 2019 1 191 M
Yield 2019 -
P/E ratio 2019 16,72
P/E ratio 2020 14,85
EV / Sales 2019 5,98x
EV / Sales 2020 4,95x
Capitalization 29 687 M
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 161 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
John J. Orloff Executive VP, Head-Research & Development
Andreas Rummelt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS36.00%25 574
CSL LIMITED14.77%64 329
BIOGEN-20.54%43 310
SAMSUNG BIOLOGICS CO LTD--.--%16 821
GRIFOLS7.90%16 048
BIOMARIN PHARMACEUTICAL INC.3.25%14 696